Pete Stavropoulos

Stock Analyst at Cantor Fitzgerald

(3.06)
# 1,358
Out of 4,981 analysts
50
Total ratings
37.5%
Success rate
5.01%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Pete Stavropoulos

Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.56
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $49.38
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107$100
Current: $24.53
Upside: +307.66%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.38
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.04
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.65
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.81
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.87
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.55
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.35
Upside: -
Initiates: Overweight
Price Target: n/a
Current: $37.86
Upside: -
Reiterates: Overweight
Price Target: $5
Current: $7.97
Upside: -37.26%
Reiterates: Overweight
Price Target: $13
Current: $1.39
Upside: +835.25%
Reiterates: Overweight
Price Target: $8
Current: $9.68
Upside: -17.36%